New Study To Evaluate Magic Mushroom's Therapeutic Potential On Autistic Adults
Psychedelics continue to garner attention as possible treatments for diverse mental health conditions. Now, Compass Pathways (NASDAQ: CMPS) will undertake a study to evaluate psilocybin’s effects on autistic adults.
